Aerovate Therapeutics, Inc. Stock price

Equities

AVTE

US0080641071

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
29.57 USD +3.75% Intraday chart for Aerovate Therapeutics, Inc. +13.73% +30.67%
Sales 2024 * - Sales 2025 * - Capitalization 794M
Net income 2024 * -90M Net income 2025 * -97M EV / Sales 2024 * -
Net cash position 2024 * 63.08M Net Debt 2025 * 6.79M EV / Sales 2025 * -
P/E ratio 2024 *
-9.31 x
P/E ratio 2025 *
-9.43 x
Employees 51
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.27%
More Fundamentals * Assessed data
Dynamic Chart
Aerovate Therapeutics Q4 Loss Widens MT
Aerovate Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Aerovate Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Aerovate Therapeutics Insider Sold Shares Worth $908,046, According to a Recent SEC Filing MT
Aerovate Therapeutics, Inc. Announces Board Changes CI
Aerovate Therapeutics Insider Sold Shares Worth $165,628, According to a Recent SEC Filing MT
Aerovate Therapeutics Insider Sold Shares Worth $203,237, According to a Recent SEC Filing MT
Aerovate Therapeutics Completes Enrollment in Phase 2b Portion of Trial for Treatment of Pulmonary Arterial Hypertension MT
Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2B Portion and Enrollment of First Patient into Phase 3 in the Impahct Trial Evaluating Av-101 for the Treatment of Pulmonary Arterial Hypertension CI
Aerovate Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Wedbush Adjusts Aerovate Therapeutics Price Target to $48 From $50, Maintains Outperform Rating MT
Aerovate Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Aerovate Therapeutics, Inc. Appoints Habib Dable as Member of Board of Directors CI
Aerovate Therapeutics, Inc.(NasdaqGM:AVTE) dropped from Russell Small Cap Comp Value Index CI
Aerovate Therapeutics, Inc.(NasdaqGM:AVTE) dropped from Russell Microcap Value Index CI
More news
1 day+13.14%
1 week+12.09%
Current month+25.74%
1 month+22.09%
3 months+19.67%
6 months+113.07%
Current year+28.24%
More quotes
1 week
24.27
Extreme 24.27
29.36
1 month
22.06
Extreme 22.06
29.36
Current year
16.74
Extreme 16.74
29.36
1 year
9.41
Extreme 9.41
29.36
3 years
7.74
Extreme 7.74
30.79
5 years
7.74
Extreme 7.74
30.79
10 years
7.74
Extreme 7.74
30.79
More quotes
Managers TitleAgeSince
Founder 48 18-07-26
Chief Executive Officer 62 21-01-31
Director of Finance/CFO 61 21-02-28
Members of the board TitleAgeSince
Director/Board Member 62 23-01-18
Director/Board Member 50 20-07-31
Chief Executive Officer 62 21-01-31
More insiders
Date Price Change Volume
24-03-28 29.57 +3.75% 216 915
24-03-27 28.5 +11.11% 922,350
24-03-26 25.65 -4.82% 271,347
24-03-25 26.95 +4.54% 224,601
24-03-22 25.78 -0.85% 90,513

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Aerovate Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing drugs that improve the lives of patients with rare cardiopulmonary diseases. Its AV-101, a dry powder inhaler, is designed to provide lung concentrations at or above those observed with the oral dose while limiting systemic levels of the drug. It provides Imatinib, marketed as Gleevec tablets, is developed for the treatment of multiple cancers. Oral imatinib also demonstrates statistically significant improvement on the primary endpoint, six-minute walk distance, and multiple secondary hemodynamic endpoints in pulmonary arterial hypertension (PAH) patients. PAH is an orphan disease characterized by increased pressure in the pulmonary arteries, vessels responsible for carrying deoxygenated blood from the heart to the lungs.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
28.5 USD
Average target price
45.83 USD
Spread / Average Target
+60.82%
Consensus
  1. Stock
  2. Equities
  3. Stock Aerovate Therapeutics, Inc. - Nasdaq